Study of Ultomiris safety during pregnancy
Part of Blood & lymphatic, Brain & nervous system, Cancer, Eyes & vision, Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at the safety of the medication Ultomiris when taken during pregnancy or breastfeeding. If you are pregnant and currently taking Ultomiris for an approved condition, this research will help gather information on how it affects you and your baby.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman who is pregnant (whether currently or in the past during this study).
- You have a medical condition for which Ultomiris (ravulizumab) is approved by your doctor.
- You have taken Ultomiris at some point during your pregnancy (or within 14 days before becoming pregnant).
- You are willing to let your doctors share your and your baby's medical records for this study.
- You are able to give your own consent (or have a parent/guardian consent if you are a minor).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational oral medication called TUL321 in healthy volunteers to see if it is safe and how the body handles it. It may help understand the drug's effects and is an early step in developing a new treatment.
This is an observational study that looks at the safety of Uplizna (satralizumab) during pregnancy for women who have neuromyelitis optica spectrum disorder (NMOSD). You may be asked to share information because your exposure to Uplizna happened during pregnancy or just before conception.
This is an observational study (no treatment is assigned) that tracks side effects and pregnancy outcomes in people taking Ubrelvy or Qulipta for migraine during pregnancy. It may help doctors better understand how these medicines affect mothers and babies.
This study collects information about pregnancies in people with multiple sclerosis (MS) who were exposed to Vumerity (diroximel fumarate) or who were not on MS medicines during pregnancy. It helps researchers understand pregnancy outcomes and safety in these situations.
This study looks at how well ravulizumab (Ultomiris) works for people with neuromyelitis optica spectrum disorder (NMOSD) by tracking symptoms and MRI scans over time. It aims to see if the drug helps control the disease in real-world use.
This study looks at how well patients with aHUS in Poland are doing after treatment with ravulizumab (Ultomiris). It is for people who have already received this drug through the national program and agree to share their health information.
Hear when a new Pregnancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.